|Year : 2019 | Volume
| Issue : 2 | Page : 131-138
Improving survival with tuberculosis & HIV treatment integration: A mini-review
Kogieleum Naidoo1, Sanisha Rampersad2, Salim Abdool Karim3
1 Centre for the AIDS Programme of Research in South Africa (CAPRISA); MRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa
2 Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa
3 Centre for the AIDS Programme of Research in South Africa (CAPRISA); MRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, USA
|Date of Submission||10-Jul-2019|
|Date of Web Publication||18-Oct-2019|
Dr Kogieleum Naidoo
Centre for the AIDS Programme of Research in South Africa (CAPRISA), Doris Duke Medical Research Institute (2nd Floor), Nelson R. Mandela School of Medicine, University of Kwazulu-Natal, Private Bag X7, Congella, Durban 4013
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Tuberculosis (TB) is a leading cause of morbidity and mortality among HIV-infected patients while HIV remains a key risk factor for the development of active TB infection. Treatment integration is a key in reducing mortality in patients with HIV-TB co-infection. However, this opportunity to improve outcomes of both infections is often missed or poorly implemented. Challenges in TB-HIV treatment integration range from complexities involving clinical management of co-infected patients to obstacles in health service-organization and prioritization. This is evident in high prevalence settings such as in sub-Saharan Africa where TB-HIV co-infection rates reach up to 80 per cent. This review discusses published literature on clinical trials and cohort studies of strategies for TB-HIV treatment integration aimed at reducing co-infection mortality. Studies published since 2009, when several treatment guidelines recommended treatment integration, were included. A total of 43 articles were identified, of which a total of 23 observational studies and nine clinical trials were informative on TB-HIV treatment integration. The data show that the survival benefit of AIDS therapy in patients infected with TB can be maximized among patients with advanced immunosuppression by starting antiretroviral therapy (ART) soon after TB treatment initiation, i.e. in patients with CD4+ cell counts <50 cells/μl. However, patients with greater CD4+ cell counts should defer initiation of ART to no less than eight weeks after initiation of TB treatment to reduce the occurrence and extent of immune reconstitution disease and subsequent hospitalization. Addressing operational challenges in integrating TB-HIV care can significantly improve patient outcomes, generate substantial public health impact by decreasing morbidity and death in settings with a high burden of HIV and TB.
Keywords: Antiretrovirals - mortality - PLHIV - pulmonary tuberculosis - treatment integration - tuberculosis-HIV co-infection
|How to cite this article:|
Naidoo K, Rampersad S, Karim SA. Improving survival with tuberculosis & HIV treatment integration: A mini-review. Indian J Med Res 2019;150:131-8
|How to cite this URL:|
Naidoo K, Rampersad S, Karim SA. Improving survival with tuberculosis & HIV treatment integration: A mini-review. Indian J Med Res [serial online] 2019 [cited 2019 Dec 16];150:131-8. Available from: http://www.ijmr.org.in/text.asp?2019/150/2/131/269540
| Introduction|| |
Tuberculosis (TB) remains the leading presenting opportunistic infection among people living with HIV (PLHIV). Globally, in 2018, despite widespread availability of effective treatment and prevention, there were 300,000 deaths from HIV-associated TB, and approximately 464,633 new and relapse cases of TB were diagnosed among PLHIV. Furthermore, in the same year, approximately 36.9 million people were known to be living with HIV, and 2-3 billion people harboured TB, most with asymptomatic latent infection .
In patients with new or latent Mycobacterium tuberculosis infection , HIV remains the strongest risk factor for TB-associated morbidity and mortality. The risk of clinically evident TB disease is highest soon after HIV seroconversion and doubles within the first year of HIV acquisition , becoming more pronounced with advancing immunosuppression . The risk of TB infection in people with HIV infection is 20-37 per cent higher compared to the HIV uninfected, and in some settings in sub-Saharan Africa, co-infection rates of TB-HIV are as high as 80 per cent .
In South Africa in 2018, the estimated number of notified TB cases alone was 322,000, occurring mainly among HIV-infected patients, and 1,908,371 in India, mainly in HIV-uninfected patients . Approximately 64 per cent of TB patients in India were aware of their HIV status, and among these patients, three per cent were HIV co-infected – equating to 36,440 individuals . While it is known that India bears the highest TB burden globally, the actual TB burden is being underreported by about 26 per cent per annum, especially among HIV-infected patients . Hence, the magnitude of TB-HIV co-infection problem and its contribution to overall morbidity and mortality in India remain underestimated. TB and HIV case identification and treatment integration remain key strategies in addressing this problem. TB is one of the most common clinical presentations of AIDS in resource-limited settings. Hence, HIV screening in patients attending TB services provides a cost-effective strategy of identifying HIV-positive patients. TB case fatality rates remain higher in HIV co-infected patients, despite effective TB treatment .
In settings where the TB and HIV epidemics overlap, significant benefits could accrue to patients, communities and programmes by simultaneously addressing these co-occurring epidemics through an integrated approach. Programmatically, this could reduce costs using existing TB care services to contribute to making antiretroviral therapy (ART) available. Despite having evidence in support of this approach demonstrating an 18-fold increase in HIV testing in TB cases compared to the previous decade, only 55 per cent of TB patients in 2015 received HIV testing globally .
The timing of ART in TB-HIV co-infected patients can present challenges of competing clinical risks and benefits. On the one hand, deferred ART after TB treatment commencement has been linked to increase mortality and AIDS disease progression, on the other hand, early initiation of ART during TB therapy raises concerns over increased risk of complexities of co-treatment such as high pill burden, immune reconstitution inflammatory syndrome (IRIS) and potentiated toxicity arising from co-administration of three antiretroviral drugs and standard four-drug anti-TB therapy . Over the last decade, substantial data have become available to address this challenge and provide an evidence-based approach that guides the timing of ART initiation in HIV-TB co-infected patients as well as on effective operational strategies for co-treatment.
| Searching the data sources|| |
Three bibliographic databases were searched from January 2009 to December 2018, including PubMed, ScienceDirect and BioMed Central for full-text articles using the initial search terms TB, HIV, mortality, antiretrovirals and timing. The search strategy was initially established in PubMed and, following modification, applied to other databases. Published literature evaluating ART timing on survival outcomes in adult patients who were co-infected with TB and HIV were selected for inclusion. Peer-reviewed full-text journal articles, published in English, were included, and fatally flawed studies, such as those with no endpoint data were excluded . Articles describing survival outcomes among drug-susceptible pulmonary TB patients also co-infected with HIV who initiated ART either before, concurrently or after TB therapy, were selected.
Eligible searched materials were evaluated for inclusion. Screening of studies followed a two-step process: study titles and abstracts were screened first and those deemed eligible for inclusion were further screened in Step 2 using the full-text article. The data were abstracted from selected articles into a standardized template. The extraction template for data collection included the names of authors, journal and year of publication, study setting, study design, study objective and key findings pertaining to the impact of ART on mortality. Studies were included if those were cohort, cross-sectional or clinical studies in which survival outcomes in TB-HIV co-infection were the primary aim or a defined outcome.
| Data synthesis and analysis|| |
Our review findings were based on study design of selected articles: data from randomized control trials from 2010 to 2018 and data from cohort and observational studies from 2009 to 2018 evaluating ART impact on mortality in co-infected patients. Search strategy for bibliographic databases was based on findings from hand-searched reference lists. Experts were consulted to verify the completeness of these electronic searches and inclusion of additional studies.
A total of 1124 citations were identified. Following removal of duplicates, a total of 1099 citations were screened. Of these, 1056 were excluded and 43 full-text articles were assessed for eligibility. A total of 11 articles were excluded for the following reasons: ART timing was not investigated (6/11), endpoint did not include death (3/11), studied extrapulmonary TB (EPTB) only (1/11) and patients not co-infected (1/11). A final selection of 32 articles, comprising 23 observational and nine randomized clinical trials, met our exclusion and inclusion criteria and were included in the review [Table 1] and [Table 2].
|Table 1: Data from randomized controlled trials evaluating the impact of antiretroviral therapy (ART) on mortality in HIV-infected tuberculosis (TB) patients: 2010-2018|
Click here to view
|Table 2: Data from cohort and observational studies evaluating the impact of antiretroviral therapy (ART) on mortality in HIV-infected tuberculosis patients: 2009-2018|
Click here to view
| Impact of ART on survival outcomes in TB-HIV co-infection: Cohort and observational studies|| |
Notwithstanding available published findings from several thousand TB-HIV co-infected patients in numerous cohort and observational studies conducted before 2010,,, conflicting evidence on the impact of concurrent ART on mortality still prevailed. While the majority of studies found reduced mortality in patients receiving co-treatment for HIV and TB ,,,,,,,,,,,,,, some studies found increased mortality in patients receiving co-treatment ,, and others found no impact of ART on mortality ,,. Initiating ART during TB therapy was associated with improved survival, improved ART uptake and continuation ,,,, and improved retention in care, particularly among those with severe immunosuppression ,.
Variation in mortality rates relative to ART timing and duration in TB treatment was also observed. While a few earlier cohort studies did not report significant differences in survival among patients initiating ART within 60 or 90 days compared to later during TB treatment ,, findings from a study demonstrated a 89 per cent reduction in risk of death in initiating early ART during TB therapy compared to delayed ART initiation , and in a retrospective cross-sectional analysis, treatment success among TB-HIV co-infected patients on ART was much higher (80%) in comparison to those who were ART naïve (54%). A 20 yr cohort study conducted between 1987 and 2004 in Spain showed better survival with simultaneous ART use and TB treatment . Death rates of 8.84 deaths/100 person-years among patients commencing ART in the first year of TB treatment were observed in a Cape Town cohort. Here, mortality peaked in the initial six months post-ART initiation, decreasing after five years to 1.14 deaths/100 person-years . Studies have also demonstrated a case fatality rate of 3.8/100 person-years within six months of incident TB diagnosis among ART patients who developed incident TB ,. In Europe and Latin America, among 1406 TB patients studied, 19 per cent died within one year of TB treatment initiation, with 71 per cent of these deaths attributable to TB. In addition, there was no difference in rates of ART initiation among those who died and survived .
| Impact of ART on survival outcomes in TB-HIV co-infection: Randomized controlled clinical trials|| |
A South African randomized study demonstrated a 56 per cent increase in survival with integrated ART and TB treatment ,. This study further described unexpectedly high mortality rates after cessation of TB therapy in co-infected patients not initiated on ART. Findings from this study were rapidly incorporated into local and global policy guidelines, recommending integration of TB and HIV treatment . Further analysis of study data demonstrated similar incidence rates of AIDS or death irrespective of whether ART was started within one month of the intensive phase of TB treatment or within a month of the continuation phase of TB treatment .
Since findings from these three landmark trials became available, several other research groups that investigated the optimal time to initiate ART in patients infected with TB have published findings from systematic reviews and meta-analyses ,,, modelling studies , clinical trials , and cohort and modelling studies which uniformly concluded that early ART in TB therapy was associated with reduced mortality compared with delayed ART; however, the survival benefit with initiating ART early was most pronounced in those with CD4+ cell counts of <50 cells/μl.
| Risk factors related to mortality among patients receiving integrated treatment for TB and HIV|| |
Studies have identified multiple factors associated with higher risk mortality among co-infected patients initiating ART. Most of the studies consistently reported that baseline CD4+ cell counts <200 cells/μl were associated with increased mortality with mortality rates substantially greater among patients with CD4+ cell count ≤50 cells/μl [hazard ratio (HR): 3.10],. Additional risk factors for mortality include (i) not having initiated ART during TB treatment , (ii) initiating ART among admitted patients, (iii) initiating ART in those with extrapulmonary and/or disseminated TB (HR: 3.70), (iv) presence of non-AIDS comorbidities , (v) initiating ART in patients undergoing mechanical ventilation (HR: 2.81), (vi) low albumin <3 g/dl (HR: 2.3),, (vii) patients not receiving co-trimoxazole prophylaxis (adjusted HR 3.03), and (viii) those interrupting TB treatment ,,.
These studies collectively demonstrated the optimal timing of ART initiation in co-infected patients, which was dependant on the degree of immunosuppression. An important limitation to note is that these findings are largely restricted to patients with pulmonary TB (PTB) susceptible to treatment, with questionable generalizability to TB presenting in other sites notably disseminated and extrapulmonary TB. While rates of PTB are approximately six times higher than EPTB globally , patients infected with HIV present with all forms of TB including disseminated or extrapulmonary TB. Tuberculous meningitis (TBM), a life-threatening form of TB disease, is associated with case fatality rates of approximately 30 per cent and severe disability among survivors, despite effective TB chemotherapy . Antiretroviral treatment commencement in HIV-infected patients who have TBM may be complicated by IRIS manifesting in the central nervous system (CNS). This results in decline in neurological functioning or even death. A randomized, double-blind, placebo-controlled trial that enrolled 253 Vietnamese participants with TBM in whom ART was started within one week or deferred until eight weeks showed similarly high mortality irrespective of whether ART was offered immediately or deferred . These findings support the recommendation of delayed ART initiation in those with HIV-associated TBM.
These studies provide clarification on optimal ART timing in patients with concurrent HIV and pulmonary TB, and indicate that patients with advanced immunosuppression (CD4+ cell count <50 cells/μl) gain the most from starting ART in the first two weeks of TB treatment ,. Patients who are stable and ambulant with higher CD4+ cell counts regardless of initiating ART earlier or later during TB therapy had comparable incidence rates of AIDS and/or death. Hence, careful consideration of other clinical factors may be warranted when weighing the benefits and risks of initiating ART in TB-HIV co-infected patients who are immunologically stable.
These studies have collectively recommended ,,,,,,,,,,,,,,,,,,,,,,,,, on the optimal timing of ART in TB patients. The majority of these strategy trials concur that ART co-administered with TB therapy improves survival irrespective of CD4+ cell count. These studies also concur that in patients with advanced immunosuppression (CD4+ cell counts <50 cells/μl), mortality was reduced when ART was started within the first two weeks of TB treatment. For patients with CD4+ cell counts >50 cells/μl, these studies advocate that ART should be deferred until after the intensive phase of TB treatment completion. This strategy does not adversely impact survival while offering a benefit of reduced morbidity from TB-IRIS and drug toxicity. An econometric analysis evaluating antiretroviral treatment scale-up and TB mortality in 41 high TB-HIV burden settings suggests that a one per cent increase in ART coverage will result in 27 per cent fewer TB deaths in one year that would not have occurred without ART .
The current WHO guidelines  cite these findings and have recommended that co-infected patients commence TB treatment first and then start ART in the next eight weeks or sooner, irrespective of CD4+ cell count. Patients with CD4+ cell counts <50 cells/μl should commence ART within two weeks of initiation of TB therapy. Patients diagnosed with HIV-associated TBM remain an exception to these recommendations, supported by findings of high death rates of up to 60 per cent, and overall poor prognosis attributable to CNS TB-IRIS.
| Conclusion|| |
High-quality evidence from several randomized studies, supported by findings from observational studies, demonstrates a substantial survival benefit of ART commencement while patients receive TB therapy among TB-HIV co-infected patients. These gains are more profound in patients with a CD4+ cell counts <50 cells/μl. High mortality irrespective of ART in patients with TBM makes this category an important exception to co-treatment. While concerns about IRIS and treatment-limiting toxicity persist, low rates of mortality associated with these conditions indicate that programmatic implementation of TB-HIV service integration can be done without the threat of worsened clinical outcomes or of increasing resources needed for the management of these complexities. Findings from multiple clinical trials have translated into local and international policy and guideline change. It is important to note that this study was focussed on published evidence on clinical integration of TB and HIV treatment. Furthermore, it is essential to recognize the controlled circumstances under which most of the studies are undertaken. Numerous operational challenges would need to be overcome for effective translation of evidence from these clinical trials into public health benefit. Despite considerable progress in generating evidence for clinical integration, there is a need for high-quality evidence guiding operational implementation that informs the successful and sustained implementation of TB and HIV service integration in various settings.
Financial support & sponsorship: None.
Conflicts of Interest: None.
| References|| |
World Health Organization. Global tuberculosis report
2018. Geneva: WHO; 2018.
Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis
Crampin AC, Floyd S, Glynn JR, Sibande F, Mulawa D, Nyondo A, et al.
Long-term follow-up of HIV-positive and HIV-negative individuals in rural Malawi. AIDS
Granich R, Akolo C, Gunneberg C, Getahun H, Williams P, Williams B. Prevention of tuberculosis in people living with HIV. Clin Infect Dis
(Suppl 3) : S215-22.
Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr
Naidoo K, Baxter C, Abdool Karim SS. When to start antiretroviral therapy during tuberculosis treatment? Curr Opin Infect Dis
Dixon-Woods M, Cavers D, Agarwal S, Annandale E, Arthur A, Harvey J, et al.
Conducting a critical interpretive synthesis of the literature on access to healthcare by vulnerable groups. BMC Med Res Methodol
Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al.
Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med
Török ME, Yen NT, Chau TT, Mai NT, Phu NH, Mai PP, et al.
Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV) – Associated tuberculous meningitis. Clin Infect Dis
Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al.
Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med
Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al.
Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med
Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al.
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med
Manosuthi W, Mankatitham W, Lueangniyomkul A, Thongyen S, Likanonsakul S, Suwanvattana P, et al.
Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: Results from the TIME study. J Acquir Immune Defic Syndr
Sinha S, Shekhar RC, Singh G, Shah N, Ahmad H, Kumar N, et al.
Early versus delayed initiation of antiretroviral therapy for indian HIV-infected individuals with tuberculosis on antituberculosis treatment. BMC Infect Dis
Mfinanga SG, Kirenga BJ, Chanda DM, Mutayoba B, Mthiyane T, Yimer G, et al.
Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): A prospective, international, randomised, placebo-controlled trial. Lancet Infect Dis
Amogne W, Aderaye G, Habtewold A, Yimer G, Makonnen E, Worku A, et al.
Efficacy and safety of antiretroviral therapy initiated one week after tuberculosis therapy in patients with CD4 counts <200 cells/μL: TB-HAART study, a randomized clinical trial. PLoS One
Velasco M, Castilla V, Sanz J, Gaspar G, Condes E, Barros C, et al.
Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr
Varma JK, Nateniyom S, Akksilp S, Mankatittham W, Sirinak C, Sattayawuthipong W, et al.
HIV care and treatment factors associated with improved survival during TB treatment in Thailand: An observational study. BMC Infect Dis
Gadkowski LB, Hamilton CD, Allen M, Fortenberry ER, Luffman J, Zeringue E, et al.
HIV-specific health care utilization and mortality among tuberculosis/HIV coinfected persons. AIDS Patient Care STDS
Franke MF, Robins JM, Mugabo J, Kaigamba F, Cain LE, Fleming JG, et al.
Effectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: A retrospective cohort study. PLoS Med
van Lettow M, Chan AK, Ginsburg AS, Tweya H, Gareta D, Njala J, et al.
Timing and uptake of ART during treatment for active tuberculosis in HIV co-infected adults in Malawi. Public Health Action
Worodria W, Massinga-Loembe M, Mazakpwe D, Luzinda K, Menten J, Van Leth F, et al.
Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy. J Acquir Immune Defic Syndr
Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS One
Sileshi B, Deyessa N, Girma B, Melese M, Suarez P. Predictors of mortality among TB-HIV co-infected patients being treated for tuberculosis in Northwest Ethiopia: A retrospective cohort study. BMC Infect Dis
Shastri S, Naik B, Shet A, Rewari B, De Costa A. TB treatment outcomes among TB-HIV co-infections in Karnataka, India: How do these compare with non-HIV tuberculosis outcomes in the province? BMC Public Health
Saraceni V, Durovni B, Cavalcante SC, Cohn S, Pacheco AG, Moulton LH, et al.
Survival of HIV patients with tuberculosis started on simultaneous or deferred HAART in the THRio cohort, Rio de Janeiro, Brazil. Braz J Infect Dis
Yang CH, Chen KJ, Tsai JJ, Lin YH, Cheng SH, Wang KF, et al.
The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study. BMC Infect Dis
Kirenga BJ, Levin J, Ayakaka I, Worodria W, Reilly N, Mumbowa F, et al.
Treatment outcomes of new tuberculosis patients hospitalized in Kampala, Uganda: A prospective cohort study. PLoS One
Mutembo S, Mutanga JN, Musokotwane K, Alisheke L, Whalen CC. Antiretroviral therapy improves survival among TB-HIV co-infected patients who have CD4+ T-cell count above 350cells/mm3. BMC Infect Dis
Nagu TJ, Aboud S, Mwiru R, Matee MI, Rao M, Fawzi WW, et al.
Tuberculosis associated mortality in a prospective cohort in sub Saharan Africa: Association with HIV and antiretroviral therapy. Int J Infect Dis
da Silva Escada RO, Velasque L, Ribeiro SR, Cardoso SW, Marins LMS, Grinsztejn E, et al.
Mortality in patients with HIV-1 and tuberculosis co-infection in Rio de Janeiro, Brazil – Associated factors and causes of death. BMC Infect Dis
Bigna JJ, Noubiap JJ, Agbor AA, Plottel CS, Billong SC, Ayong AP, et al.
Early mortality during initial treatment of tuberculosis in patients co-infected with HIV at the yaoundé central hospital, Cameroon: An 8-year retrospective cohort study (2006-2013). PLoS One
Kaplan R, Hermans S, Caldwell J, Jennings K, Bekker LG, Wood R. HIV and TB co-infection in the ART era: CD4 count distributions and TB case fatality in Cape Town. BMC Infect Dis
Nglazi MD, Bekker LG, Wood R, Kaplan R. The impact of HIV status and antiretroviral treatment on TB treatment outcomes of new tuberculosis patients attending co-located TB and ART services in South Africa: A retrospective cohort study. BMC Infect Dis
Han SH, Zhou J, Lee MP, Zhao H, Chen YM, Kumarasamy N, et al.
Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: Results from the TREAT Asia HIV observational database. HIV Med
Stockdale AJ, Nkuranga J, Török ME, Faragher B, Lalloo DG. Initiation of antiretroviral therapy in HIV-infected tuberculosis patients in rural Kenya: An observational study. Trop Med Int Health
Podlekareva DN, Efsen AM, Schultze A, Post FA, Skrahina AM, Panteleev A, et al.
Tuberculosis-related mortality in people living with HIV in Europe and Latin America: An international cohort study. Lancet HIV
Ansa GA, Walley JD, Siddiqi K, Wei X. Assessing the impact of TB/HIV services integration on TB treatment outcomes and their relevance in TB/HIV monitoring in Ghana. Infect Dis Poverty
Adamu AL, Gadanya MA, Abubakar IS, Jibo AM, Bello MM, Gajida AU, et al.
High mortality among tuberculosis patients on treatment in Nigeria: A retrospective cohort study. BMC Infect Dis
Thwaites GE, Duc Bang N, Huy Dung N, Thi Quy H, Thi Tuong Oanh D, Thi Cam Thoa N, et al.
The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with tuberculous meningitis. J Infect Dis
World Health Organization. Global tuberculosis report 2014
. Geneva: WHO; 2014.
Saraceni V, Cohn S, Cavalcante SC, Pacheco AG, Moulton LH, Chaisson RE, et al.
Prevalent tuberculosis at HIV diagnosis in Rio de Janeiro, Brazil: The TB/HIV in Rio (THRio) cohort. J Acquir Immune Defic Syndr
[Table 1], [Table 2]